ERBB2 and breast cancer: In particular, 92.2% of (47/51) patients with HER2+ BC and BM ≥ 3 cm presented with neurological symptoms compared to 64.5% (98/152) with BM < 3 cm (p < 0.001; chi-square test; Supplementary Table 2).